News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

2011

  • Dec 22, 2011 Antiemetic Agent, Kytril®, Obtained Approval for Additional Indication
    [PDF 183KB]
  • Dec 20, 2011 Supplemental Biologics License Application Submitted to FDA for ACTEMRA®,
    a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
    Regarding Adult Rheumatoid Arthritis Indication
    [PDF 181KB]
  • Dec 19, 2011 Personnel Strategy toward Becoming
    A “Top Japanese Pharmaceutical Company”
    [PDF 502KB]
  • Dec 15, 2011 Chugai to Establish
    “Chugai Pharmabody Research Pte. Ltd.” in Singapore,
    a New Company for Generating New Antibody Drugs
    [PDF 181KB]
  • Dec 14, 2011 Bisphosphonate Antiresorptive Agent,
    Ibandronate Sodium Hydrate Injection,
    Demonstrates Efficacy in Osteoporosis in Phase II/III Trial
    [PDF 21KB]
  • Dec 14, 2011 Announcing Change of Parent Company and Largest Shareholder (Principal Shareholder)
    [PDF 104KB]
  • Dec 06, 2011 Personnel Changes
    [PDF 37KB]
  • Nov 28, 2011 Introduction of iPad2 to Activities for Providing Information to Medical Professionals
    [PDF 182KB]
  • Nov 25, 2011 Anti-Cancer Agent, Herceptin®
    Obtained Approval for Additional Indication and Dosage and Administration
    [PDF 176KB]
  • Nov 01, 2011 Supply Plan of "Tamiflu®" Anti-influenza Drug
    [PDF 43KB]
  • Nov 01, 2011 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 108KB]
  • Oct 13, 2011 F. Hoffmann-La Roche Announces Third Quarter Sales 2011
    [PDF 16KB]
  • Oct 06, 2011 Chugai Presents an Anti-Cancer Charity "Medicine and Humor 2011"
    [PDF 199KB]
  • Sep 30, 2011 Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin®
    for Chemotherapy-Induced Anemia
    [PDF 96KB]
  • Sep 26, 2011 Anti-Cancer Agent, Avastin®
    Obtained Approval for Additional Indication and Dosage and Administration of
    “Inoperable or Recurrent Breast Cancer“
    [PDF 175KB]
  • Sep 26, 2011 Peginterferon alfa-2a “Pegasys®
    Approved for Additional Indication of “Chronic Active Hepatitis B”
    [PDF 187KB]
  • Sep 16, 2011 Immunosuppressive Agent, CellCept® Obtains Approval for Additional Pediatric
    Dosage and Administration for Prophylaxis of Organ Rejection in Renal Transplants
    [PDF 201KB]
  • Sep 08, 2011 Chugai Establishes Endowed Course at Waseda University
    – Focus on Japan’s Leading Cause of Death: Cancer –
    [PDF 68KB]
  • Sep 02, 2011 Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds
    Utilizing the Personalized Healthcare Strategy
    [PDF 212KB]
  • Aug 19, 2011 Detection of Radioactive Material from RDF Incineration Ashes
    at Chugai’s Fuji-Gotemba Research Laboratories
    [PDF 189KB]
  • Aug 15, 2011 Chugai to In-license BRAF Inhibitor Vemurafenib
    [PDF 176KB]
  • Aug 10, 2011 Antiemetic Agent, Kytril®
    Filed for Additional Indication By
    "Application Based on Evidence in the Public Domain"
    [PDF 171KB]
  • Aug 08, 2011 Organizational and Personnel Changes
    [PDF 224KB]
  • Aug 03, 2011 Roche's RoACTEMRA Approved in Europe for
    Children Living with a Rare and Severe Form of Arthritis
    [PDF 160KB]
  • Jul 21, 2011 Differences between Consolidated Financial Outlook and Actual Results of Half Year ended June 30, 2011, and Revision of Consolidated Financial Outlook for Fiscal Year 2011 ending December 31, 2011
    [PDF 72KB]
  • Jul 21, 2011 F. Hoffmann-La Roche Announces 2011 Half Year Results
    [PDF 21KB]
  • Jul 19, 2011 Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®"
    Subcutaneous Injection Demonstrates Efficacy
    in Rheumatoid Arthritis in Phase III Clinical Study
    [PDF 42KB]
  • Jul 19, 2011 Chugai Launches a Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe”
    [PDF 371KB]
  • Jul 15, 2011 New Drug Application Filed for
    Recombinant Human Deoxyribonuclease I (rhDNase) "Pulmozyme"
    [PDF 239KB]
  • Jul 13, 2011 Update on the Impact of the Great East Japan Earthquake
    [PDF 22KB]
  • Jul 05, 2011 Roche Returns Development and Marketing Rights of SGLT2 Inhibitor “CSG452”to Chugai
    [PDF 16KB]
  • Jul 01, 2011 Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of
    “Pancreatic Cancer Not Amenable to Curative Resection“
    and Measures for Proper Use
    [PDF 237KB]
  • Jul 01, 2011 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of
    Compensated Liver Cirrhosis Related to Hepatitis C
    [PDF 282KB]
  • Jun 14, 2011 Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
    [PDF 50KB]
  • Jun 13, 2011 Update on the Application of Epogin® in Chemotherapy-Induced Anemia
    [PDF 103KB]
  • May 27, 2011 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 79KB]
  • May 26, 2011 RoActemra Could Change the Current Standard of Treatment for
    People Living with Rheumatoid Arthritis
    [PDF 193KB]
  • May 23, 2011 RoActemra Offers a New Option for
    Children Living with a Rare and Severe Form of Arthritis
    [PDF 65KB]
  • May 16, 2011 Immunosuppressive Agent, CellCept® Filed for Pediatric Dosage and
    Administration for Prevention of Organ Rejection in Renal Transplant
    by “Application Based on Evidence in the Public Domain”
    [PDF 179KB]
  • May 09, 2011 Anti-Cancer Agent, Herceptin®
    Filed for Additional Indication, and Dosage and Administration
    By "New Drug Application Based on Evidence in the Public Domain"
    [PDF 168KB]
  • Apr 22, 2011 Long-Acting Erythropoiesis Stimulating Agent,
    “Mircera® Injection Syringe,” Approved in Japan
    [PDF 186KB]
  • Apr 21, 2011 Revision of Financial Outlook for Fiscal Year 2011
    (January 1 – December 31, 2011)
    [PDF 21KB]
  • Apr 20, 2011 Chronic Hepatitis C Treatment, Pegasys®, Designated for Priority Review
    by Ministry of Health, Labour and Welfare for the Indication of Chronic Hepatitis B
    [PDF 173KB]
  • Apr 18, 2011 FDA Approves ACTEMRA for the Treatment of
    Systemic Juvenile Idiopathic Arthritis (SJIA)
    [PDF 159KB]
  • Apr 14, 2011 F. Hoffmann-La Roche Announces First Quarter Sales 2011
    [PDF 63KB]
  • Apr 08, 2011 Launch of the Osteoporosis Agent “Edirol® Capsule”
    [PDF 204KB]
  • Apr 04, 2011 Impact of the Great East Japan Earthquake (No.3)
    [PDF 17KB]
  • Mar 23, 2011 Donation of "Tamiflu®" Anti-influenza Drug for the Support of
    the Sufferers of the 2011 Off the Pacific Coast of Tohoku Earthquake
    [PDF 188KB]
  • Mar 18, 2011 Impact of the 2011 off the Pacific coast of Tohoku Earthquake (No.2)
    [PDF 36KB]
  • Mar 14, 2011 Impact of the 2011 off the Pacific coast of Tohoku Earthquake
    [PDF 37KB]
  • Mar 14, 2011 Relief Efforts Support for the Disaster Area
    Struck by the 2011 Off the Pacific Coast of Tohoku Earthquake
    [PDF 167KB]
  • Mar 10, 2011 Anti-Cancer Agent, Herceptin®
    Obtained Approval for Additional Indication of Advanced or Recurrent
    Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection
    [PDF 175KB]
  • Feb 23, 2011 Anti-Cancer Agent, Xeloda® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection
    [PDF 172KB]
  • Feb 02, 2011 Notice Regarding Dividend
    [PDF 60KB]
  • Feb 02, 2011 Information about Appointment of a New Accounting Auditor
    [PDF 75KB]
  • Feb 02, 2011 Personnel Changes
    [PDF 51KB]
  • Feb 02, 2011 Organizational and Personnel Changes
    [PDF 214KB]
  • Feb 02, 2011 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2010
    [PDF 67KB]
  • Feb 01, 2011 Pegasys ®, and Copegus ®, Designated for Priority Review by MHLW
    for the Indication of Compensated Liver Cirrhosis Related to Hepatitis C
    [PDF 181KB]
  • Jan 27, 2011 Chronic Hepatitis C Treatment, Pegasys®,
    Filed for Additional Indication of Chronic Hepatitis B
    [PDF 173KB]
  • Jan 24, 2011 Chugai Launches A New Disease Awareness Website for Rheumatoid Arthritis
    - “Heidi, a Girl of the Alps” navigates through the website -
    [PDF 278KB]
  • Jan 21, 2011 An Active Vitamin D3 Derivative “Edirol®,” Approved in Japan
    [PDF 27KB]
  • Jan 06, 2011 FDA Grants Supplemental Approval for ACTEMRA
    [PDF 107KB]
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top